Method for the treatment of multiple sclerosis
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.
1. A method of inhibiting or reducing lymphocyte activation and proliferation in a subject undergoing autoimmune demyelination, which comprises administering to the subject a therapeutically effective amount of a 2ME2 compound having the following formula:
wherein R a is selected from the group consisting of —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CCCH 3 , —CHCH—CH 3 , and —CH 2 —CHCH 2 .
2. The method of claim 1 , which further comprises administering to the subject a second agent selected from the group consisting of a steroid, an anti-inflammatory compound, an immunosuppressive compound, and an antioxidant.
3. The method of claim 2 , wherein the second agent is beta-interferon.
4. The method of claim 2 , wherein the second agent is glatiramer acetate.
5. The method of claim 2 , wherein the second agent is lipoic acid.
6. The method of claim 2 , wherein the second agent is a monoclonal antibody.
7. The method of claim 2 , wherein the second agent is selected from the group consisting of daclizumab, rituximab, and natalizumab.
8. The method of claim 2 , wherein the second agent is sanglifehrin A or a compound having cyclophilin D inhibitory activity.
9. The method of claim 1 , wherein administration of the 2ME2 compound is oral, parenteral, transdermal, topical, intravenous, subcutaneous, intramuscular, intradermal, ophthalmic, epidural, intratracheal, sublingual, buccal, rectal, vaginal, nasal, or inhalation.
10. A method of inhibiting or reducing NFATc1 nuclear translocation and NFAT-dependent gene transcription in a subject undergoing autoimmune demyelination, which comprises administering to the subject a therapeutically effective amount of a 2ME2 compound having the following formula:
wherein R a is selected from the group consisting of —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CCCH 3 , —CHCH—CH 3 , and —CH 2 —CHCH 2 .
11. The method of claim 10 , which further comprises administering to the subject a second agent selected from the group consisting of a steroid, an anti-inflammatory compound, an immunosuppressive compound, and an antioxidant.
12. The method of claim 11 , wherein the second agent is beta-interferon.
13. The method of claim 11 , wherein the second agent is glatiramer acetate.
14. The method of claim 11 , wherein the second agent is lipoic acid.
15. The method of claim 11 , wherein the second agent is a monoclonal antibody.
16. The method of claim 11 , wherein the second agent is selected from the group consisting of daclizumab, rituximab, and natalizumab.
17. The method of claim 11 , wherein the second agent is sanglifehrin A or a compound having cyclophilin D inhibitory activity.
18. The method of claim 10 , wherein administration of the 2ME2 compound is oral, parenteral, transdermal, topical, intravenous, subcutaneous, intramuscular, intradermal, ophthalmic, epidural, intratracheal, sublingual, buccal, rectal, vaginal, nasal, or inhalation.
19. A method of inhibiting or reducing T cell cytokine production in a subject undergoing autoimmune demyelination, which comprises administering to the subject a therapeutically effective amount of a 2ME2 compound having the following formula:
wherein R a is selected from the group consisting of —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CCCH 3 , —CHCH—CH 3 , and —CH 2 —CHCH 2 .
20. The method of claim 19 , which further comprises administering to the subject a second agent selected from the group consisting of a steroid, an anti-inflammatory compound, an immunosuppressive compound, and an antioxidant.
21. The method of claim 20 , wherein the second agent is beta-interferon.
22. The method of claim 20 , wherein the second agent is glatiramer acetate.
23. The method of claim 20 , wherein the second agent is lipoic acid.
24. The method of claim 20 , wherein the second agent is a monoclonal antibody.
25. The method of claim 20 , wherein the second agent is selected from the group consisting of daclizumab, rituximab, and natalizumab.
26. The method of claim 20 , wherein the second agent is sanglifehrin A or a compound having cyclophilin D inhibitory activity.
27. The method of claim 19 , wherein administration of the 2ME2 compound is oral, parenteral, transdermal, topical, intravenous, subcutaneous, intramuscular, intradermal, ophthalmic, epidural, intratracheal, sublingual, buccal, rectal, vaginal, nasal, or inhalation.